Magnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosis.

Magnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosis.

Show other versions (1)

Interferon-β (IFN-β) drugs are considered to derive their beneficial effects on multiple sclerosis (MS) progression via their antiinflammatory properties, but the precise mechanism of action remains unclear. Here, we sought to discover how IFN-β impacts on inflammation-associated aggravation of MS-l...

Bibliografske podrobnosti
Main Authors:	Serres, S, Bristow, C, de Pablos, R, Merkler, D, Soto, MS, Sibson, N, Anthony, D
Format:	Journal article
Jezik:	English
Izdano:	2013

Podobne knjige/članki

Magnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosis
od: Serres, S, et al.
Izdano: (2013)

Contribution of peripheral IL-1beta expression in the systemic reactivation of focal MOG-EAE lesions in rat brain
od: Serres, S, et al.
Izdano: (2009)

CONTRIBUTION OF PERIPHERAL IL-1BETA EXPRESSION IN THE SYSTEMIC REACTIVATION OF FOCAL MOG-EAE LESIONS IN RAT BRAIN
od: Serres, S, et al.
Izdano: (2009)

Interferon beta treatment of multiple sclerosis.
od: Markovitz, D
Izdano: (1994)

VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis.
od: Serres, S, et al.
Izdano: (2011)

Beta-interferons in multiple sclerosis
od: Aggarwal Sourabh, et al.
Izdano: (2010-01-01)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
od: Mohamed Rayen Ganouni, et al.
Izdano: (2023-10-01)

Reactivation of a focal EAE lesion by a systemic inflammatory response
od: Serres, S, et al.
Izdano: (2007)

Functional role of endothelial adhesion molecules in the early stages of brain metastasis.
od: Soto, MS, et al.
Izdano: (2014)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
od: Sibley, W, et al.
Izdano: (1994)

Detection of primary and secondary brain tumours using molecularly-targeted magnetic resonance imaging
od: Serres, S, et al.
Izdano: (2016)

Treatment of multiple sclerosis with interferon beta-1b - Reply
od: Sibley, W, et al.
Izdano: (1997)

Treatment of multiple sclerosis with interferon beta-1 b.
od: Abdul-Ahad, A, et al.
Izdano: (1997)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
od: Castrop F, et al.
Izdano: (2013-09-01)

Depression and anxiety in patients with multiple sclerosis treated with interferon-beta or fingolimod: Role of indoleamine 2,3-dioxygenase and pro-inflammatory cytokines
od: Carlos B. Tauil, et al.
Izdano: (2020-12-01)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
od: Sørensen, P, et al.
Izdano: (2010)

A cost-utility analysis of interferon beta for multiple sclerosis.
od: Parkin, et al.
Izdano: (1998-01-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
od: Masoud Mohammad Malekzadeh, et al.
Izdano: (2020-06-01)

THE INFLUENCE OF NEUTRALIZING ANTIBODIES TO INTERFERON-BETA ON PROGRESSION OF MULTIPLE SCLEROSIS
od: V. Yu. Lizhdvoy, et al.
Izdano: (2016-07-01)

Levels of circulating cytokines in children with multiple sclerosis with different effectiveness of interferon therapy
od: T. V. Radygina, et al.
Izdano: (2024-01-01)

Comparison of MRI signatures in pattern I and II multiple sclerosis models.
od: Serres, S, et al.
Izdano: (2009)

Curcumin as an add-on therapy for multiple sclerosis in patients receiving interferon-beta therapy
od: A. D. Kukushkina, et al.
Izdano: (2024-08-01)

Proteotranscriptomic analyses reveal distinct interferon-beta signaling pathways and therapeutic targets in choroidal neovascularization
od: Yuxiang Hu, et al.
Izdano: (2023-03-01)

Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
od: Lampasona, V, et al.
Izdano: (2003)

The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis
od: Ebers, G, et al.
Izdano: (1997)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
od: Dian HE, et al.
Izdano: (2014-09-01)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
od: De Caro Maria, et al.
Izdano: (2006-12-01)

Beta-interferons in multiple sclerosis: A single center experience in India
od: Gupta Salil, et al.
Izdano: (2010-01-01)

Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis
od: Ivanović Jovana, et al.
Izdano: (2019-01-01)

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
od: Elmazny A, et al.
Izdano: (2020-03-01)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
od: Cocco E, et al.
Izdano: (2015-05-01)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
od: Ebers, G, et al.
Izdano: (1998)

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
od: Mark S. Freedman, et al.
Izdano: (2024-01-01)

beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis
od: Parry, A, et al.
Izdano: (2002)

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
od: Parry, A, et al.
Izdano: (2003)

Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis
od: E Gibbons, et al.
Izdano: (2015-01-01)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
od: Alexandre Xavier, et al.
Izdano: (2023-05-01)

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
od: Miraç Ayşen Ünsal
Izdano: (2019-03-01)

The Effect of Beta Interferon on the Expression of miR-145 in Patients with Multiple Sclerosis
od: Naeim Ehtesham, et al.
Izdano: (2016-11-01)

Interferon-beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription
od: Keivan Basiri, et al.
Izdano: (2012-02-01)